Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of advanced therapies for intermediate- to high-risk pulmonary embolism with improved right ventricular function on outpatient follow-up among survivors.

Frontiers in cardiovascular medicine·2026
Same author

Pathway for the Diagnosis and Management of Pericardial Disease: Contemporary Perspective.

Critical pathways in cardiology·2026
Same author

Neutrophil-to-lymphocyte ratio in patients with low-flow aortic stenosis undergoing transcatheter aortic valve implantation.

Journal of cardiology·2026
Same author

Continuous-wave Doppler interrogation in valvular heart disease: pearls and pitfalls.

European heart journal. Imaging methods and practice·2026
Same author

Raghib Syndrome Physiology Revealed by Multimodality Cardiac Imaging.

JACC. Case reports·2026
Same author

Flow Normalization and Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement Across Low-Flow Aortic Stenosis Phenotypes.

The American journal of cardiology·2026
Same journal

Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.

Journal of hypertension·2026
Same journal

Erratum: Feasibility of the extended, 48-h ambulatory blood pressure monitoring in hemodialysis patients: a multicenter study.

Journal of hypertension·2026
Same journal

Erratum: Neurofibromatosis 2 alleviates ferroptosis and fibrosis in the aortas of spontaneously hypertensive rats through the Yes-associated protein pathway.

Journal of hypertension·2026
Same journal

Reply to comment: Limited public understanding of the risk factors and complications of hypertension.

Journal of hypertension·2026
Same journal

What magnesium depletion score can tell us about arterial stiffness.

Journal of hypertension·2026
Same journal

Nephron deficit as susceptibility, not determinism.

Journal of hypertension·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Beta-blockers for blood pressure augmentation

Dan G Halpern, Vikram Agarwal, Edgar Argulian

    Journal of Hypertension
    |January 11, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 15, 2026

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
    08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022